Home » Topics » BioWorld Science, Dermatologic

BioWorld Science, Dermatologic
RSS

Vasogen prepares Canadian trial of VAS-972 for psoriasis

Feb. 2, 2001

IDEC-131 commences phase II trial for psoriasis

Jan. 30, 2001

Isotechnika's ISAtx-247 to be developed for third indication: psoriasis

Jan. 26, 2001

Chemokine receptor antagonists designed at the former SmithKline Beecham

Jan. 24, 2001

Cellegy accelerates U.S. filing for Anogesic

Jan. 24, 2001

BioMarin exercises option to product candidate for burns and wounds

Jan. 24, 2001

Phase II trial of P-45 falls short of primary objective

Jan. 23, 2001

Modex completes patient enrollment in EpiDex phase II trial

Jan. 22, 2001

Wyeth-Ayerst seeks FDA approval of new indication of Alesse

Jan. 22, 2001

Meditech licenses Solaraze from SkyePharma

Jan. 22, 2001

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 10, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 7, 2026
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...
Orexin OX2 receptor agonists disclosed in Vertex Pharmaceuticals patent
BioWorld Science
Vertex Pharmaceuticals Inc. has patented new macrocyclic sulfonamide orexin OX2 receptor agonists potentially useful for the treatment of amyotrophic lateral...